3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Lung Neoplasms
12
Small Cell Lung Carcinoma
4
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Mesothelioma
2
Thymoma
1
Somatostatinoma
1
Recurrence
1
Pheochromocytoma
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Insulinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Glucagonoma
1
Gastrointestinal Neoplasms
1
Gastrinoma
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Medullary
1
Carcinoma, Large Cell
1
Carcinoma, Islet Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Surveys and Questionnaires
5
Nivolumab
5
pembrolizumab
3
atezolizumab
3
Radiosurgery
3
pralsetinib
2
pertuzumab
2
cobimetinib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Exercise
2
Drug Therapy
2
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
talazoparib
1
selpercatinib
1
repotrectinib
1
remune
1
ponatinib
1
pemigatinib
1
pazopanib
1
palbociclib
1
osimertinib
1
motexafin gadolinium
1
montanide ISA 51
1
itacitinib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Everolimus
×
Thoracic
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled